Weighing the Evidence: A Pharmacy Approach to Stroke Prevention in Obese Patients with Non-Valvular Atrial Fibrillation

CMEO Webcast

Live Webcast: Sunday, December 6, 2020
6:30 PM - 8:00 PM ET

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Monday, December 6, 2021

Register for Activity

Faculty


Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC (Moderator)
Executive Director of Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA

Kazuhiko Kido, PharmD, MS, BCCP, BCPS Kazuhiko Kido, PharmD, MS, BCCP, BCPS 
Clinical Assistant Professor of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, WV

Statement of Need

Atrial fibrillation (AF) is estimated to affect over 5 million people in the United States and is associated with a five-fold increase in the relative risk of stroke. Obesity is an independent risk factor for cardiovascular disease (CVD) and is also associated with increased risk of developing non-valvular AF (NVAF). Patients with comorbid NVAF and obesity need appropriate management of their individual stroke risk. Guidelines for anticoagulant therapy in this patient population have been limited due to lack of available data.

Recent publications of subgroup analyses of randomized controlled trials (RCTs) and retrospective observation cohort studies have provided data on the efficacy and safety of direct oral anticoagulants (DOACs) versus warfarin in obese and extremely obese patients with NVAF. Because pharmacists are a trusted resource and have frequent access to patients, it is imperative that they are well-versed in the latest published data as well as existing guidelines and prescribing information for use of DOACs and warfarin to prevent stroke in patients with NVAF.

In this CME Outfitters virtual symposium, expert faculty will review key aspects of the prescribing information, guidelines, and recently published safety and efficacy data for DOACs and warfarin in order to enable pharmacists and other clinicians to support evidence-based therapeutic treatment decisions in obese patients with NVAF.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Assess existing guidelines and U.S. prescribing information for use of DOACs and warfarin to prevent stroke in obese patients with NVAF.
  • Evaluate safety and efficacy data for DOACs and warfarin in obese patients with NVAF.
  • Counsel obese patients with NVAF on risks and benefits of DOACs and warfarin to optimize adherence and health outcomes.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Assess existing guidelines and U.S. prescribing information for use of DOACs and warfarin to prevent stroke in obese patients with NVAF.
  • Evaluate safety and efficacy data for DOACs and warfarin in obese patients with NVAF.
  • Counsel obese patients with NVAF on risks and benefits of DOACs and warfarin to optimize adherence and health outcomes.

Financial Support

Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance

Target Audience

Health-system pharmacists and community pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number: Live: 0376-0000-20-161-L01-P

Type: knowledge-based

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bhatt reports that he is a consultant for Abbott; Afimmune; Amarin Corporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eisai Inc.; Ethicon USA, LLC; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd.; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC.; Medtronic; PhaseBio Pharmaceuticals, Inc.; Pfizer Inc.; PLx Pharma Inc.; Regeneron; Roche; Sanofi-Aventis U.S. LLC; Synaptic Pharmaceutical Corp.; and The Medicines Company.

Dr. Kido has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Rachel Speer, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MM-109-120620-90